Oxbryta is the first medicine approved in Europe ... The confounder for both GBT and Novartis' hopes for their drug could be genetic therapies for SCD, which offer a one-shot treatment for the ...

Pfizer is on the brink of announcing a deal to buy Global Blood Therapeutics (GBT) and its oral therapy Oxbryta for sickle cell disease for around $5 billion, according to press reports.

The analysts also said the Oxbryta withdrawal raises questions about what will happen to Pfizer's other sickle cell disease treatment in development, GBT-601. That oral drug, which Pfizer also ...

known as GBT-601, showed promise in a mid-stage study late last year, and could represent a “potential step-wise evolution over Oxbryta.” Pfizer shares were little changed in New York.

The company offers Oxbryta tablets, an oral once-daily therapy for SCD. It also evaluates pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and ...